Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

• Status: Completed
• Trial end date: 2013-05-01

Summary

Primary Objective:

• To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide

Secondary Objectives:

• To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide

• To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide

• To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide

• To document the safety of Otamixaban as compared to UFH + eptifibatide

• To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Calcium heparin; Eptifibatide; Heparin; Otamixaban